Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70367 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Siren Morken und 20 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Clinic, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Adenocarcinoma, Carcinoma, Neuroendocrine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ipsen, The Norwegian Cancer Society, Nordic Cancer Union.
Abstract (Originalsprache)
There is limited data regarding the rare and aggressive colorectal neuroendocrine carcinoma (CR‐NEC). In this large prospective study, molecular–clinical characteristics and treatment outcomes following palliative chemotherapy are reported for 163 metastatic CR‐NEC patients, with a comparison to a population‐based prospective cohort of 263 metastatic colorectal adenocarcinoma (CR‐AC) patients. Eighty‐three percent of CR‐NEC received first‐line platinum‐etoposide, while 98% of CR‐AC patients received first‐line fluorouracil‐based chemotherapy. Disease control rate across all first‐line regimens in CR‐NEC and CR‐AC was 43% vs. 74%, immediate progressive disease 46% vs. 15%, progression‐free survival 2.4 months (m) (95% CI 2.1–3.3) vs. 7.7 m (95% CI 6.9–8.5), and overall survival 6.7 m (95% CI 5.6–8.8) vs. 16.8 m (95% CI 13.7–20.3), all, p < .001. CR‐NEC more often had synchronous metastases, worse performance status, and symptom burden at treatment initiation than CR‐AC (all, p < .001). Two‐year survival was 9% vs. 37% in CR‐NEC and CR‐AC ( p < .001). BRAF mutations were frequent in CR‐NEC and CR‐AC (26% vs. 20%, p = .153) and associated with shorter OS in CR‐NEC and CR‐AC ( p = .025 and p = .003). KRAS mutations were less frequent in CR‐NEC than CR‐AC (34% vs. 45%, p = .041), but only associated with shorter OS in rectal NEC ( p = .04). The frequencies of APC and TP53 mutations were similar between the cohorts and did not impact survival. Metastatic CR‐NEC and CR‐AC are clinically distinct, with NEC demonstrating more aggressive features, limited treatment effect, and worse prognosis. Although they share important driver mutations, the underlying reason for their marked clinical differences remains unclear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cancer Clinic, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
- Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
ORCID-Profile: Siren Morken, Morten Ladekarl, Stian Knappskog, Halfdan Sorbye
Förderung
- Ipsen
- The Norwegian Cancer Society
- Nordic Cancer Union
- Novartis
- The Western Norway Regional Health Authority
Zitieren
APA
Morken, S., Langer, S. W., Hjortland, G. O., Sundlöv, A., Hofsli, E., Ladekarl, M., Tabaksblat, E., Vestermark, L. W., Svensson, J., Knigge, U., Nunes, L., Glimelius, B., Pfeiffer, P., Aasebø, K., Assmus, J., Vassella, E., Lothe, I. M. B., Couvelard, A., Perren, A., …, & Sorbye, H. (2026). Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas. International Journal of Cancer. https://doi.org/10.1002/ijc.70367
Vancouver
Morken S, Langer SW, Hjortland GO, Sundlöv A, Hofsli E, Ladekarl M, et al. Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas. International Journal of Cancer. 2026. doi:10.1002/ijc.70367
BibTeX
@article{Morken2026,
author = {Morken, Siren and Langer, Seppo W and Hjortland, Geir Olav and Sundlöv, Anna and Hofsli, Eva and Ladekarl, Morten and Tabaksblat, Elizaveta and Vestermark, Lene Weber and Svensson, Johanna and Knigge, Ulrich and Nunes, Luís and Glimelius, Bengt and Pfeiffer, Per and Aasebø, Kristine and Assmus, Jörg and Vassella, Erik and Lothe, Inger Marie Bowitz and Couvelard, Anne and Perren, Aurel and Knappskog, Stian and Sorbye, Halfdan},
title = {Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70367}
}
EUVIMED